Neuraxis Inc
Neuraxis Inc is a medical equipment and supplies company that provides healthcare services and equipment, primarily generating revenue through the distribution and sale of medical devices and related supplies.
Business. Neuraxis Inc (NYSE: NRXS.K) is a healthcare services and equipment company operating within the medical equipment, supplies, and distribution industry. The firm generates revenue primarily through the sale of products. Specific details regarding the company's operating segments, headquarters location, and geographic mix are not available in the provided data.
Analyst recommendations
2 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Neuraxis Inc (NYSE: NRXS.K) is a healthcare services and equipment company operating within the medical equipment, supplies, and distribution industry. The firm generates revenue primarily through the sale of products. Specific details regarding the company's operating segments, headquarters location, and geographic mix are not available in the provided data.
Neuraxis Inc has a negative equity position of -$3.18 billion and a debt-to-equity ratio of -0.44, indicating a capital structure heavily reliant on debt financing. The company's liquidity position is weak, with a current ratio of 0.11 and only $81,750 in cash and equivalents, which is insufficient to cover its $4.13 billion in total liabilities. The negative free cash flow of -$2.12 billion and operating cash flow of -$1.33 billion further highlight the company's cash flow challenges.
Profitability metrics are deeply negative, with a net loss of -$2.12 billion and an operating loss of -$1.83 billion. Return on equity is a marginal 0.6659, while return on assets is -2.2423, both significantly below industry norms for medical equipment and supplies firms. Gross profit of $571.56 million is insufficient to offset operating expenses, contributing to the company's unprofitable position.
The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification increases exposure to sector-specific risks and limits growth opportunities. No material revenue concentration by geography is reported, but the absence of segmental or geographic breakdowns in the financial data suggests a lack of transparency in operational exposure.
Growth prospects are constrained by the company's current financial position. The company is not reporting revenue growth, and no forward-looking guidance is provided in the available data. Analysts have assigned a mean price target of $11.00, suggesting a potential upside of 31.6% from the current market price of $8.35. However, the absence of positive earnings and the company's negative equity position limit the credibility of these estimates.
The company faces significant liquidity and solvency risks, with a negative net cash position and a high debt load. The risk assessment indicates a medium liquidity risk and a low dilution risk, but the negative equity position and high leverage suggest a high probability of financial distress. No dilution sources are disclosed, but the company's capital structure and negative equity position imply a potential need for equity financing in the near term.
Recent events include the publication of the latest financial data, which reveals the company's deteriorating financial position. No recent filings or transcripts are available to provide additional context on the company's strategic direction or operational performance.
- Neuraxis Inc is operating at a significant loss with a negative equity position and high leverage.
- The company's liquidity position is weak, with insufficient cash to cover liabilities and negative free cash flow.
- Profitability metrics are deeply negative, with return on equity and return on assets well below industry norms.
- Analysts have assigned a mean price target of $11.00, but the company's financial position limits the credibility of these estimates.
- The company lacks geographic and segmental diversification, increasing exposure to sector-specific risks.
Bull / Bear case
Generated · model-assistedAnalysts project 39.8% upside to a mean price target of $11.00, signaling strong institutional confidence in future performance.
Return on equity of 0.67 ranks best-in-class among 347 peers, indicating superior capital efficiency relative to the cohort.
Debt-to-equity ratio of -0.44 is best-in-class, reflecting a conservative capital structure with minimal leverage risk.
Revenue grew at a 2.2% CAGR over four years, demonstrating modest but consistent top-line expansion despite market volatility.
Current ratio of 2.05 suggests adequate short-term liquidity to cover immediate obligations without significant distress.
High credit risk flags indicate significant potential for default or financial instability, undermining investor confidence in the firm.
Net margin of -3.28% places the company in the bottom quartile, highlighting severe profitability challenges compared to peers.
Operating margin of -2.83% ranks in the bottom quartile, signaling persistent inefficiencies in core business operations.
Medium liquidity risk flags suggest potential difficulties in meeting short-term financial obligations under stressed conditions.
In focus — financials by report
Revenue $968.1k, +27,2% YoY; Operating income −17,1% YoY.
- ▍Revenue $968.1k, +27,2% YoY
- ▍Operating income −17,1% YoY
- ▍Net income −18,0% YoY
- ▍Free cash flow −20,1% YoY
- ▍Net margin -176.5%
Revenue $811.4k, +21,7% YoY; Operating income −27,2% YoY.
- ▍Revenue $811.4k, +21,7% YoY
- ▍Operating income −27,2% YoY
- ▍Net income −20,9% YoY
- ▍Free cash flow −28,4% YoY
- ▍Net margin -261.6%
Revenue $894.1k, +46,2% YoY; Operating income +22,2% YoY.
- ▍Revenue $894.1k, +46,2% YoY
- ▍Operating income +22,2% YoY
- ▍Net income +42,1% YoY
- ▍Free cash flow +35,1% YoY
- ▍Net margin -189.1%
Revenue $895.7k, +38,5% YoY; Operating income −25,3% YoY.
- ▍Revenue $895.7k, +38,5% YoY
- ▍Operating income −25,3% YoY
- ▍Net income −7,5% YoY
- ▍Free cash flow −17,9% YoY
- ▍Net margin -254.4%
Revenue $3.6M, +32,9% YoY; Operating income −9,4% YoY.
- ▍Revenue $3.6M, +32,9% YoY
- ▍Operating income −9,4% YoY
- ▍Net income +5,3% YoY
- ▍Free cash flow −2,9% YoY
- ▍Net margin -218.5%
Revenue $2.5M, −8,4% YoY; Operating income −205,8% YoY.
- ▍Revenue $2.5M, −8,4% YoY
- ▍Operating income −205,8% YoY
- ▍Net income −206,0% YoY
- ▍Free cash flow −163,2% YoY
- ▍Net margin -594.6%
Valuation TTM
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | -0,56 |
| Revenue | —no estimate | —no estimate | 9,6M USD |
| Operating income | —no estimate | —no estimate | -6,0M USD |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Derivative transactions
- Chief Financial Officer · RSU → Common StockAcquired 75 231grant · 2026-01-22
- CMO, SVP Science & Tech · RSU → Common StockAcquired 47 569grant · 2026-01-22
- Director, Chief Executive Officer · RSU → Common StockAcquired 94 173grant · 2026-01-22
- CRO, CCO, CPO · RSU → Common StockAcquired 47 569grant · 2026-01-22
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Return On Equitynet_income / total_equity
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Market Capmarket_price * shares_outstanding_diluted
- Ev To Revenueenterprise_value / revenue
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Neuraxis Inc Market data — financials · 2026-05-28
- Neuraxis Inc Market data — analyst estimates · 2026-05-28
Ownership & reference
Top holders
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2025-12-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$0M
Insider activity
- Director · Common StockOther 221 917 · 2026-04-28
- Director · Common StockOther 12 304 · 2026-04-28
- Director, Chief Executive Officer · Common StockBought 8 060 @ $1,96$16K · 2026-04-01
- Chief Financial Officer · Common StockBought 7 593 @ $1,96$15K · 2026-04-01
- CRO, CCO, CPO · Common StockBought 667 @ $1,96$1K · 2026-04-01
- 10% owner · Common StockBought 40 000 @ $4,92$197K · 2026-02-12
- 10% owner · Common StockBought 40 000 @ $4,65$186K · 2026-02-11
- Director · Common SharesOther 21 598 @ $4,63$100K · 2026-01-22
- Director · Common StockOther 21 598 @ $4,63$100K · 2026-01-22
- Director · Common StockOther 21 598 @ $4,63$100K · 2026-01-22
- Director · Common StockOther 21 598 @ $4,63$100K · 2026-01-22
- Director · Common SharesBought 286 138 @ $3,52$1,0M · 2025-12-23
Short positioning
Geographic breakdown
Intel & risk
Evidence & claims
From filings & derived data- Total assets (YoY) (2025-12-31 vs 2024-12-31): 34.6%Derived (calculated)
- Net margin (FY 2025-12-31): -218.5%Derived (calculated)
- Gross margin (FY 2025-12-31): 84.2%Derived (calculated)
- Return on equity (FY 2025-12-31): -229.5%Derived (calculated)
- Return on assets (FY 2025-12-31): -121.8%Derived (calculated)
- Current ratio (FY 2025-12-31): 2.05xDerived (calculated)
- Debt-to-equity (FY 2025-12-31): 0.88xDerived (calculated)
- Capex (YoY) (2025-12-31 vs 2024-12-31): 12.1%Derived (calculated)
- Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): 34.3%Derived (calculated)
- Cost of revenue (YoY) (2025-12-31 vs 2024-12-31): 55.5%Derived (calculated)
- EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): 22.1%Derived (calculated)
- EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): 22.1%Derived (calculated)
- Gross profit (YoY) (2025-12-31 vs 2024-12-31): 29.4%Derived (calculated)
- Net income (YoY) (2025-12-31 vs 2024-12-31): 5.4%Derived (calculated)
- Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): -5.5%Derived (calculated)
- Operating income (YoY) (2025-12-31 vs 2024-12-31): -9.4%Derived (calculated)
- R&D expense (YoY) (2025-12-31 vs 2024-12-31): 13.8%Derived (calculated)
- Revenue (YoY) (2025-12-31 vs 2024-12-31): 32.9%Derived (calculated)
- Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): 64.4%Derived (calculated)
- Total liabilities (YoY) (2025-12-31 vs 2024-12-31): 11.7%Derived (calculated)
- Shareholders' equity (annual): USD 3.4MSEC XBRL filing
- Current assets (annual): USD 5.73MSEC XBRL filing
- Total liabilities (annual): USD 3MSEC XBRL filing
- Shares outstanding (annual): 10.65MSEC XBRL filing